Aurobindo Pharma is currently trading at Rs. 430.00, up by 0.40 points or 0.09% from its previous closing of Rs. 429.60 on the BSE.
The scrip opened at Rs. 434.75 and has touched a high and low of Rs. 449.50 and Rs. 425.10 respectively. So far 224590 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 838.00 on 30-Apr-2019 and a 52 week low of Rs. 389.70 on 14-Nov-2019.
Last one week high and low of the scrip stood at Rs. 449.50 and Rs. 412.90 respectively. The current market cap of the company is Rs. 26074.27 crore.
The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 34.95% and 13.18% respectively.
The company has been recognized as the company of the year for its outstanding development, innovation and success over the past year
Aurobindo Pharma has won two prestigious awards at the 6th Global Generics & Biosimilars Awards 2019 for ‘Company of the Year and Acquisition of the Year’.
The company has been recognized as the Company of the Year for its outstanding development, innovation and success over the past year. The Acquisition of the Year award was given to the company following its acquisition of Sandoz Inc., USA's dermatology and oral solids businesses in the United States.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
